Anti-CD80 (Galiximab), Human IgG1, lambda Antibody

Anti-CD80 (Galiximab), Human IgG1, lambda Antibodyis available at Gentaur for Next week Delivery.

Description: Galiximab is a primatized mAb which consists of human constant and primate (cynomolgus macaque) variable regions and binds specifically to CD80. CD80 is a surface glycoprotein and a member of the B7 family of co-stimulatory molecules. CD80 antigen regulates T cell activation (through interacting with CD28 or CD152) and is expressed transiently in antigen-presenting cells, T cells and normal B cells, and expressed constitutively on various subtypes of B-cell lymphomas. Galiximab acts to decrease in cell proliferation, inhibition of the constitutively active NF-κB pathway, increase in apoptosis and ADCC against various B-cell lymphoma cell lines. Galiximab affects CD28 and CD152 interactions with CD80.

Immunogen Sequence:Galiximab was prepared by immunizing cynomolgus monkeys with recombinant CD80 antigen. The variable regions of the light and heavy chains were then cloned by being incorporated into a cassette vector (N5LG1) containing human constant region genes and subsequently transfected into the Dg44 CHO cell line

Target Alternative Name:B7-1; T-lymphocyte activation antigen CD80; Activation B7-1 antigen; BB1; CTLA-4 counter-receptor B7.1; B7

Species Reactivities:Human

Tag Line:Recombinant monoclonal antibody manufactured using Recombinant Platform with variable regions from the therapeutic antibody IDEC-114 (Galiximab) to detect CD80 expression in humans

Formulation:Supplied in PBS, pH 7.5

Purification: SOURCE: CHO cells

Application:Block, Immunohistochemistry (IHC), Immunofluorescence (IF), Immunoprecipitation (IP), Western Blotting, Modulate, Flow Cytometry, ELISA

Positive Control:/

Application And Usages:WB, ELISA, IP, IF, IHC, FC, Block, Modulate

Handling:The antibody solution should be gently mixed before use.